EFFECT OF ZOLEDRONIC ACID AND PAMIDRONATE ON SKELETAL-RELATED EVENTS AND MORTALITY IN WOMEN WITH BONE METASTASES FROM BREAST CANCER IN A MANAGED CARE PLAN: A RETROSPECTIVE DATABASE ANALYSIS

被引：0
|
作者：
Henk, H. J. [2 ]
Kaura, S. [1 ]
机构：
[1] Novartis Pharmaceut, Florham Pk, NJ USA
[2] i3 Innovus, Eden Prairie, MN USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)71910-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A253 / A253
页数：1
相关论文
共 50 条
  • [1] Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan
    Henk, H.
    Kaura, S.
    EJC SUPPLEMENTS, 2010, 8 (03): : 200 - 201
  • [2] RETROSPECTIVE DATABASE ANALYSIS OF THE EFFECT OF ZOLEDRONIC ACID ON SKELETAL-RELATED EVENTS IN MEN WITH PROSTATE CANCER AND BONE METASTASES
    Henk, H. J.
    Kaura, S.
    VALUE IN HEALTH, 2010, 13 (07) : A254 - A254
  • [3] A COMPARISON OF DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN BREAST CANCER PATIENTS WITH BONE METASTASES
    Fujiwara, Yasuhiro
    Stopeck, Alison
    de Boer, Richard
    Lichinitser, Mikhail
    Tonkin, Katia
    Yardley, Denise
    Fan, Michelle
    Jiang, Qi
    Jun, Susie
    Dansey, Roger
    Braun, Ada
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [4] A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases
    Stopeck, A.
    de Boer, R.
    Fujiwara, Y.
    Lichinitser, M.
    Tonkin, K.
    Yardley, D.
    Fan, M.
    Jiang, Q.
    Jun, S.
    Dansey, R.
    Braun, A.
    CANCER RESEARCH, 2009, 69 (24) : 490S - 490S
  • [5] Analysis of Risk Factors for Development of Skeletal-Related Events in Women with Bone Metastases from NSCLC and Breast Cancer
    Lumachi, Franco
    Ubiali, Paolo
    Del Conte, Alessandro
    Mazza, Francesco
    Basso, Stefano
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S680 - S681
  • [6] Risk of Skeletal-Related Events in Patients with Advanced Prostate Cancer Treated with Pamidronate or Zoledronic Acid
    Spence, Michele M.
    Hui, Rita L.
    Chan, James
    Schottinger, Joanne E.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (09) : 1384 - 1388
  • [7] Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events
    Sherer, Jeffrey T.
    Adamus, Andrea T.
    PHARMACOTHERAPY, 2007, 27 (02): : 207 - 217
  • [8] Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma
    Reed, SD
    Radeva, JI
    Glendenning, GA
    Coleman, RE
    Schulman, KA
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (01): : 8 - 16
  • [9] Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
    Lipton, A.
    Fizazi, K.
    Stopeck, A. T.
    Henry, D. H.
    Smith, M. R.
    Shore, N.
    Martin, M.
    Vadhan-Raj, S.
    Brown, J. E.
    Richardson, G. E.
    Saad, F.
    Yardley, D. A.
    Zhou, K.
    Balakumaran, A.
    Braun, A.
    EUROPEAN JOURNAL OF CANCER, 2016, 53 : 75 - 83
  • [10] Retrospective Database Analysis of the Effect of Zoledronic Acid (ZOL) On Skeletal-Related Events (SREs) in Patients (Patients) with Multiple Myeloma (MM)
    Henk, Henry J.
    Kaura, Satyin
    Perez, Jose Ricardo
    Becker, Laura
    BLOOD, 2009, 114 (22) : 1493 - 1493
12345